Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by In silico Analysis of Differential Gene Expression
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Background: Oral squamous cell carcinoma (OSCC) and oral lichen planus (OLP) are two separate conditions affecting the mouth and result in varying clinical outcomes and levels of malignancy. Achieving early diagnosis and effective therapy planning requires the identification of reliable diagnostic biomarkers for these disorders. MicroRNAs (miRNAs) have recently received attention as powerful biomarkers for various illnesses, including cancer. In particular, miR-483-5p is a promising diagnostic and prognostic biomarker in various cancers. Therefore, this study aimed to investigate the role of serum miR-483-5p in the diagnosis and prognosis of OLP and OSCC patients by in silico analysis of differential gene expression. Methods: GSE23558 and GSE52130 data sets were selected, and differential gene expression analysis was performed using microarray data from GSE52130 and GSE23558. The analysis focused on comparing OLP and OSCC samples with normal samples. The genes intersected through the differential gene expression analysis were then extracted to determine the overlapping genes among the upregulated or downregulated DEGs. The downregulated genes among the DEGs were subsequently imported into the miRWalk database to search for potential target genes of miRNA 483-5p that lacked validation. To gain insight into the biological pathways associated with the DEGs, we conducted pathway analysis utilizing tools, such as Enrichr. Additionally, the cellular components associated with these DEGs were investigated by analyzing the String database. On the other hand, blood serum samples were collected from 35 OSCC patients, 34 OLP patients, and 34 healthy volunteers. The expression level of miR-483-5p was determined using quantitative reverse transcription polymerase chain reaction (RT-qPCR). The Kruskal-Wallis test was utilized to investigate the considerable correlation. Moreover, this study explored the prognostic value of miR-483-5p through its association with clinicopathological parameters in OSCC patients. Results: The results showed that serum expression of miR-483-5p was considerably higher in OSCC patients compared to OLP patients and healthy controls (p 0.0001) and that this difference was statistically significant. Furthermore, elevated miR-483-5p expression was associated with tumor size, lymph node metastasis, and stage of tumor nodal metastasis in OSCC patients (p 0.001, p 0.038, and p 0.0001, respectively). In silico analysis found 71 upregulated genes at the intersection of upregulated DEGs and 44 downregulated genes at the intersection of downregulated DEGs, offering insight into the potential underlying mechanisms of miR-483-5p’s engagement in OSCC and OLP. The majority of these DEGs were found to be involved in autophagy pathways, but DEGs involved in the histidine metabolism pathway showed significant results. Most of these DEGs were located in the extracellular region. After screening for downregulated genes that were invalidated, miRNA 483-5p had 7 target genes. Conclusion: This study demonstrates the potential of serum miR-483-5p as a promising diagnostic and prognostic biomarker in OSCC and OLP patients. Its upregulation in OSCC patients and its association with advanced tumor stage and potential metastasis suggest the involvement of miR-483-5p in critical signaling pathways involved in cell proliferation, apoptosis, and cell cycle regulation, making it a reliable indicator of disease progression. Nevertheless, additional experimental studies are essential to validate these findings and establish a foundation for the advancement of targeted therapies and personalized treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a previous study, it was shown that hsa-mir-133b is a promising biomarker for oral squamous cell carcinoma [25].”
From The impact of mutations on TP53 protein and MicroRNA expression in HNSCC: Novel insights for diagnostic and therapeutic strategies (2025) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yong, F. L., Law, C. W., & Wang, C. W. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-280 · Cited by 176
MiR‐483–5p suppresses the proliferation of glioma cells via directly targeting ERK1
Wang, L., Shi, M., Hou, S., Ding, B., Liu, L., Ji, X., Zhang, J., & Deng, Y. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.035 · Cited by 87
Research works printed but not linked: 41
- Zhou Y.; Hong L.; Prediction value of miR-483 and miR-214 in prognosis and multidrug resistance of esophageal squamous cell carcinoma. Genet Test Mol Biomarkers 2013,17(6),470-474 · DOI
- Rachagani S.; Macha M.A.; Menning M.S.; Dey P.; Pai P.; Smith L.M.; Mo Y.Y.; Batra S.K.; Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Oncotarget 2015,6(37),40295-40309 · DOI
- Amirkhah R.; Schmitz U.; Linnebacher M.; Wolkenhauer O.; Farazmand A.; MicroRNA-mRNA interactions in colorectal cancer and their role in tumor progression. Genes Chromoso Cancer 2015,54(3),129-141 · DOI
- Farshbaf A.; Zare R.; Mohajertehran F.; Mohtasham N.; New diagnostic molecular markers and biomarkers in odontogenic tumors. Mol Biol Rep 2021,48(4),3617-3628 · DOI
- Hong L.; Han Y.; Li S.; Yang J.; Zheng J.; Zhang H.; Zhao Q.; Wu K.; Fan D.; The malignant phenotype-associated microRNA in gastroenteric, hepatobiliary and pancreatic carcinomas. Expert Opin Biol Ther 2010,10(12),1693-1701 · DOI
- Liu M.; Roth A.; Yu M.; Morris R.; Bersani F.; Rivera M.N.; Lu J.; Shioda T.; Vasudevan S.; Ramaswamy S.; Maheswaran S.; Diederichs S.; Haber D.A.; The IGF2 intronic miR-483 selectively enhances transcription from IGF2 fetal promoters and enhances tumorigenesis. Genes Dev 2013,27(23),2543-2548 · DOI · Paper page
- Watson J.A.; Bryan K.; Williams R.; Popov S.; Vujanic G.; Coulomb A.; Boccon-Gibod L.; Graf N.; Pritchard-Jones K.; O’Sullivan M.; miRNA profiles as a predictor of chemoresponsiveness in Wilms’ tumor blastema. PLoS One 2013,8(1),e53417 · DOI
- Yu X.; Li Z.; Chan M.T.V.; Wu W.K.K.; The roles of microRNAs in Wilms’ tumors. Tumour Biol 2016,37(2),1445-1450 · DOI
- chen Y.; Wang H.; Zhu S.; Lan X.; miR-483-5p promotes esophageal cancer progression by targeting KCNQ1. Biochem Biophys Res Commun 2020,531(4),615-621 · DOI
- Zhou W.; Yang W.; Ma J.; Zhang H.; Li Z.; Zhang L.; Liu J.; Han Z.; Wang H.; Hong L.; Role of miR-483 in digestive tract cancers: from basic research to clinical value. J Cancer 2018,9(2),407-414 · DOI
- Che G.; Gao H.; Tian J.; Hu Q.; Xie H.; Zhang Y.; MicroRNA-483-3p promotes proliferation, migration, and invasion and induces chemoresistance of wilms’ tumor cells. Pediatr Dev Pathol 2020,23(2),144-151 · DOI
- Zhou W.; Yang W.; Yang J.; Zhu H.; Duan L.; Wang X.; Li Y.; Niu L.; Xiao S.; Zhang R.; Yang J.; Hong L.; miR-483 promotes the development of colorectal cancer by inhibiting the expression level of EI24. Mol Med Rep 2021,24(2),567 · DOI
- Ghazi N.; Aali N.; Shahrokhi V.R.; Mohajertehran F.; Saghravanian N.; Relative expression of SOX2 and OCT4 in oral squamous cell carcinoma and oral epithelial dysplasia. Rep Biochem Mol Biol 2020,9(2),171-179 · doi:10.29252/rbmb.9.2.171
- Al Rawi N.; Elmabrouk N.; Abu Kou R.; Mkadmi S.; Rizvi Z.; Hamdoon Z.; The role of differentially expressed salivary microRNA in oral squamous cell carcinoma. A systematic review. Arch Oral Biol 2021,125,105108 · DOI
- Ghosh P.; Jana A.; Thomas J.; Erosive oral lichen planus inflicts higher cellular stress than reticular type. J Oral Maxillofac Pathol 2021,25(2),279-285 · DOI
- Mohtasham N.; Ayatollahi H.; Saghravanian N.; Zare R.; Shakeri M.T.; Sahebkar A.; Mohajertehran F.; Evaluation of tissue and serum expression levels of lactate dehydrogenase isoenzymes in patients with head and neck squamous cell carcinoma. Anticancer Agents Med Chem 2020,19(17),2072-2078 · doi:10.2174/1871520619666191014160818
- Inchanalkar M.; Srivatsa S.; Ambatipudi S.; Bhosale P.G.; Patil A.; Schäffer A.A.; Beerenwinkel N.; Mahimkar M.B.; Genome-wide DNA methylation profiling of HPV-negative leukoplakia and gingivobuccal complex cancers. Clin Epigenetics 2023,15(1),93 · DOI
- Danielsson K.; Coates P.; Ebrahimi M.; Nylander E.; Wahlin Y.; Nylander K.; Genes involved in epithelial differentiation and development are differentially expressed in oral and genital lichen planus epithelium compared to normal epithelium. Acta Derm Venereol 2014,94(5),526-530 · DOI
- Szklarczyk D.; Kirsch R.; Koutrouli M.; Nastou K.; Mehryary F.; Hachilif R.; Gable A.L.; Fang T.; Doncheva N.T.; Pyysalo S.; Bork P.; Jensen L.J.; von Mering C.; The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 2023,51(D1),D638-D646 · DOI · Paper page
- Shannon P.; Markiel A.; Ozier O.; Baliga N.S.; Wang J.T.; Ramage D.; Amin N.; Schwikowski B.; Ideker T.; Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res 2003,13(11),2498-2504 · DOI · Paper page
- Murugan A.K.; Munirajan A.K.; Tsuchida N.; Ras oncogenes in oral cancer: The past 20 years. Oral Oncol 2012,48(5),383-392 · DOI
- Mohtasham N.; Anvari K.; Memar B.; Saghravanian N.; Ghazi N.; Bagherpour A.; Ramtin M.; Expression of E-cadherin and matrix metalloproteinase-9 in oral squamous cell carcinoma and histologically negative surgical margins and association with clinicopathological parameters. Rom J Morphol Embryol 2014,55(1),117-121
- Ries J.; Vairaktaris E.; Kintopp R.; Baran C.; Neukam F.W.; Nkenke E.; Alterations in miRNA expression patterns in whole blood of OSCC patients. In Vivo 2014,28(5),851-861
- Wang W.; Wang M.; Ahmed M.M.S.; Zhao Y.; Wu H.; Musa M.; Chen X.; FAM3B serves as a biomarker for the development and malignancy of oral lichen planus. Int J Gen Med 2022,15,763-776 · DOI
- Li Q.L.; Mao J.; Meng X.Y.; Comprehensive characterization of immune landscape based on tumor microenvironment for oral squamous cell carcinoma prognosis. Vaccines 2022,10(9),1521 · DOI
- Wang L.; Wu W.; Chen J.; Li Y.; Xu M.; Cai Y.; miR-122 and miR-199 synergistically promote autophagy in oral lichen planus by targeting the Akt/mTOR pathway. Int J Mol Med 2019,43(3),1373-1381 · DOI
- Tan Y-Q; Zhang J; Du G-F; Lu R; Chen G-Y; Zhou G; Altered autophagy-associated genes expression in T cells of oral lichen planus correlated with clinical features. Mediat Inflamm 2016,2016,4867368 · doi:10.1155/2016/4867368
- Dong W.; Chen Y.; Qian N.; Sima G.; Zhang J.; Guo Z.; Wang C.; SATB2 knockdown decreases hypoxia-induced autophagy and stemness in oral squamous cell carcinoma. Oncol Lett 2020,20(1),794-802 · DOI
- Chen G.; Liu H.; Zhang Y.; Liang J.; Zhu Y.; Zhang M.; Yu D.; Wang C.; Hou J.; Silencing PFKP inhibits starvation-induced autophagy, glycolysis, and epithelial mesenchymal transition in oral squamous cell carcinoma. Exp Cell Res 2018,370(1),46-57 · DOI
- Song Q.; Xu Y.; Yang C.; Chen Z.; Jia C.; Chen J.; Zhang Y.; Lai P.; Fan X.; Zhou X.; Lin J.; Li M.; Ma W.; Luo S.; Bai X.; miR-483-5p promotes invasion and metastasis of lung adenocarcinoma by targeting RhoGDI1 and ALCAM. Cancer Res 2014,74(11),3031-3042 · DOI
- Huang G.; Zhang J.; Qing G.; Liu D.; Wang X.; Chen Y.; Wu Y.; Li Y.; Guo S.; Downregulation of miR-483-5p inhibits TGF-β1-induced EMT by targeting RhoGDI1 in pulmonary fibrosis. Mol Med Rep 2021,24(1),538 · DOI
- Li X.Z.; Tu Y.J.; Zhou T.; Zhang J.B.; Xiao R.W.; Yang D.W.; Zhang P.F.; You P.T.; Zheng X.H.; MicroRNA-483-5p predicts poor prognosis and promotes cancer metastasis by targeting EGR3 in nasopharyngeal carcinoma. Front Oncol 2021,11,720835 · DOI
- Abdelaleem O.O.; Fouad N.A.; Shaker O.G.; Ahmed T.I.; Abdelghaffar N.K.; Eid H.M.; Mohamed A.A.; Elebiary A.M.; Mohamed M.M.; Mahmoud R.H.; Serum miR-224, miR-760, miR-483-5p, miR-378 and miR-375 as potential novel biomarkers in rheumatoid arthritis. Int J Clin Pract 2021,75(11),e14651 · DOI
- Shao H.; Zhang Y.; Yan J.; Ban X.; Fan X.; Chang X.; Lu Z.; Wu Y.; Zong L.; Mo S.; Yu S.; Chen J.; Upregulated microRNA-483-3p is an early event in Pancreatic Ductal Adenocarcinoma (PDAC) and as a powerful liquid biopsy biomarker in PDAC. OncoTargets Ther 2021,14,2163-2175 · DOI
- Giuliani A.; Matacchione G.; Ramini D.; Di Rosa M.; Bonfigli A.R.; Sabbatinelli J.; Monsurrò V.; Recchioni R.; Marcheselli F.; Marchegiani F.; Piacenza F.; Cardelli M.; Galeazzi R.; Pomponio G.; Ferrarini A.; Gabrielli A.; Svegliati Baroni S.; Moretti M.; Sarzani R.; Giordano P.; Cherubini A.; Corsonello A.; Antonicelli R.; Procopio A.D.; Ferracin M.; Bonafè M.; Lattanzio F.; Olivieri F.; Circulating miR-320b and miR-483-5p levels are associated with COVID-19 in-hospital mortality. Mech Ageing Dev 2022,202,111636 · DOI
- Yang Z.G.; Ma X.D.; He Z.H.; Guo Y.; miR-483-5p promotes prostate cancer cell proliferation and invasion by targeting RBM5. Int Braz J Urol 2017,43(6),1060-1067 · DOI
- Xu H.; Yang Y.; Zhao H.; Yang X.; Luo Y.; Ren Y.; Liu W.; Li N.; Serum miR-483-5p: A novel diagnostic and prognostic biomarker for patients with oral squamous cell carcinoma. Tumour Biol 2016,37(1),447-453 · DOI
- Bertero T.; Bourget-Ponzio I.; Puissant A.; Loubat A.; Mari B.; Meneguzzi G.; Auberger P.; Barbry P.; Ponzio G.; Rezzonico R.; Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties. Cell Cycle 2013,12(14),2183-2193 · DOI · Paper page
- Ghantous Y.; Schussel J.L.; Brait M.; Tobacco and alcohol-induced epigenetic changes in oral carcinoma. Curr Opin Oncol 2018,30(3),152-158 · DOI
- Rumgay H.; Murphy N.; Ferrari P.; Soerjomataram I.; Alcohol and cancer: Epidemiology and biological mechanisms. Nutrients 2021,13(9),3173 · DOI · Paper page
- Yete S.; D’Souza W.; Saranath D.; High-risk human papillomavirus in oral cancer: Clinical implications. Oncology 2018,94(3),133-141 · doi:10.1159/000485322
Cited by
Mahmoud, A. A., Raih, M. F., Sage, E. E., Ali, Q. M., Suliman, O. H., Ibrahim, S. A. E., Mohamed, O., Abdelrazeg, S., & Mohamed, S. B. (2025) · PLOS One · doi:10.1371/journal.pone.0307859 · Cited by 4
Metadata
- Authors
- Soltaninezhad, P., Arab, F., Mohtasham, N., FakherBaheri, M., Kavishahi, N. N., Aghaee-Bakhtiari, S. H., Zare-Mahmoodabadi, R., Pakfetrat, A., Taban, K. I., & Mohajertehran, F.
- Affiliations
- Dental Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Medical Genetics and Molecular Medicine, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- Oral and Maxillofacial Diseases Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Medical Genetics, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
- Department of Medical Biotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
- Department of Oral and Maxillofacial Pathology, School of Dentistry, Mashhad University of Medical Sciences, Mashhad, Iran
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2024-02
- Volume
- 30
- Issue
- 4
- Pages
- 310-322
- ISSN
- 1381-6128
- Cited by
- 4
- References
- 2
- Language
- en
- Funders
- Vice Chancellor for Research, MUMS, Mashhad, Iran (991611)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by In silico Analysis of Differential Gene Expression. https://app.cochat.ai/papers/10.2174/0113816128276149240108163407
- The paper
- Soltaninezhad, P., Arab, F., Mohtasham, N., FakherBaheri, M., Kavishahi, N. N., Aghaee-Bakhtiari, S. H., Zare-Mahmoodabadi, R., Pakfetrat, A., Taban, K. I., & Mohajertehran, F. (2024). Unveiling the Potential of Serum MiR-483-5p: A Promising Diagnostic and Prognostic Biomarker in OLP and OSCC Patients by In silico Analysis of Differential Gene Expression. Current Pharmaceutical Design. https://doi.org/10.2174/0113816128276149240108163407
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.